Shots:
- Lead Pharma receives ~$11.86M upfront and is eligible to receive funding and ~$307.9 as research, development, regulatory and commercial milestones along with royalties on sales of small molecules
- The companies will collaborate in research activities up to the selection of a pre-clinical candidate after which Roche will be responsible for the development and global commercialization
- The R&D collaboration builds on Lead Pharma’s expertise in the discovery, design, and optimization of small-molecule treatments
Click here to read full press release/ article | Ref: PRNewswire | Image: PRNewswire
The post Roche Signs a License Agreement with Lead Pharma to Develop Oral Therapies for Immune-Mediated Diseases first appeared on PharmaShots.
